Anti EGFR antibodies (such as cetuximab or panimab) combined with chemotherapy is an effective treatment for patients with RAS wild-type MCRC only.473 Since downstream KRAS mutations exist in about 50% of CRC, the effectiveness of EGFR inhibitor combination therapy is usually limited by intrinsic drug resistance. This evidence concerns the gene KRAS and colorectal carcinoma.